Last checked at 4 May 2021 07:00
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Posting of Annual Report and Accounts, and Notice of AGM
Brighton, United Kingdom - 4 May 2021 - Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that the following documents are now available on the Company's website at www.destinypharma.com
· Annual Report and Accounts of the Company for the year ended 31 December 2020
· Notice of the 2021 Annual General Meeting ("AGM") which is to be held at 11.00am BST on 3 June, 2021
Printed copies of both documents will be posted to shareholders today.
Whilst in normal circumstances the Board values the opportunity to engage with shareholders in person at its AGM, on this occasion the Board feels it is appropriate to advise shareholders against travelling to attend the AGM in person and, instead, to submit proxy votes as early as possible because, as matters currently stand, shareholders will not be granted access to the AGM. Shareholders are strongly advised to appoint the Chairman of the AGM as their proxy. If the situation changes then shareholders will be notified via the Company's website at www.destinypharma.com and via RNS announcement.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com
finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information on the company, please visit https://www.destinypharma.com